Literature DB >> 23348114

Position paper on tuberculosis screening in patients with immune mediated inflammatory diseases candidates for biological therapy.

R Duarte1, S Campainha, J Cotter, B Rosa, P Varela, A Correia, H Canhão, J E Fonseca.   

Abstract

UNLABELLED: Chronic immunosuppression is a known risk factor for tuberculosis. Our aim was to reach a consensus on screening and prevention of tuberculosis in patients with immune mediated inflammatory diseases candidates to biologic therapy.
METHODS: Critical appraisal of the literature and expert opinion on immunosuppressive therapies and risk of tuberculosis. RESULTS AND
CONCLUSION: The currently recommended method for screening is the tuberculin skin test and the interferon gamma assay, after exclusion of active tuberculosis. Positively screened patients should be treated for latent tuberculosis infection. Patients may start biological therapy after 1 to 2 months, as long as they are strictly adhering to and tolerating their preventive regimen.

Entities:  

Mesh:

Year:  2012        PMID: 23348114

Source DB:  PubMed          Journal:  Acta Reumatol Port        ISSN: 0303-464X            Impact factor:   1.290


  7 in total

1.  Diagnosis of latent tuberculosis infection with T-SPOT(®).TB in a predominantly immigrant population with rheumatologic disorders.

Authors:  Patricio Escalante; Kirstin J Kooda; Rizwana Khan; San San Aye; Stratos Christianakis; Daniel G Arkfeld; Glenn R Ehresmann; Jens J Kort; Brenda E Jones
Journal:  Lung       Date:  2014-10-16       Impact factor: 2.584

Review 2.  Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment.

Authors:  Dong Il Park; Tadakazu Hisamatsu; Minhu Chen; Siew Chien Ng; Choon Jin Ooi; Shu Chen Wei; Rupa Banerjee; Ida Normiha Hilmi; Yoon Tae Jeen; Dong Soo Han; Hyo Jong Kim; Zhihua Ran; Kaichun Wu; Jiaming Qian; Pin-Jin Hu; Katsuyoshi Matsuoka; Akira Andoh; Yasuo Suzuki; Kentaro Sugano; Mamoru Watanabe; Toshifumi Hibi; Amarender S Puri; Suk-Kyun Yang
Journal:  Intest Res       Date:  2018-01-18

Review 3.  Review article: latent tuberculosis in patients with inflammatory bowel diseases receiving immunosuppression-risks, screening, diagnosis and management.

Authors:  Sasha R Fehily; Aysha H Al-Ani; Jonathan Abdelmalak; Clarissa Rentch; Eva Zhang; Justin T Denholm; Douglas Johnson; Siew C Ng; Vishal Sharma; David T Rubin; Peter R Gibson; Britt Christensen
Journal:  Aliment Pharmacol Ther       Date:  2022-05-20       Impact factor: 9.524

Review 4.  A guide to prepare patients with inflammatory bowel diseases for anti-TNF-α therapy.

Authors:  Júlio Maria Fonseca Chebli; Pedro Duarte Gaburri; Liliana Andrade Chebli; Tarsila Campanha da Rocha Ribeiro; André Luiz Tavares Pinto; Orlando Ambrogini Júnior; Adérson Omar Mourão Cintra Damião
Journal:  Med Sci Monit       Date:  2014-03-26

5.  Screening and prevention for latent tuberculosis in immunosuppressed patients at risk for tuberculosis: a systematic review of clinical practice guidelines.

Authors:  Tasnim Hasan; Eric Au; Sharon Chen; Allison Tong; Germaine Wong
Journal:  BMJ Open       Date:  2018-09-12       Impact factor: 2.692

6.  Simultaneous Adalimumab and Antitubercular Treatment for Latent Tubercular Infection: An Experience from Nepal.

Authors:  Binit Vaidya; Shweta Nakarmi
Journal:  Int J Rheumatol       Date:  2019-04-01

7.  Tuberculosis and TNF-α inhibitors in children: how to manage a fine balance.

Authors:  Sara Parigi; Amelia Licari; Sara Manti; Gian Luigi Marseglia; Maria Angela Tosca; Michele Miraglia Del Giudice; Carlo Caffarelli; Mauro Calvani; Alberto Martelli; Fabio Cardinale; Claudio Cravidi; Marzia Duse; Elena Chiappini
Journal:  Acta Biomed       Date:  2020-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.